Search Results
Phase II trial of XPro1595 for the treatment of Alzheimer’s disease
XPro1595 Webinar on Expanded Phase 1b Data in Patients with Alzheimer’s Disease
How XPro1595 ("XPro") is Unique to Other TNF Inhibitors
Phase II/III GAIN trial results: atuzaginstat for disease modification in Alzheimer’s disease
Webinar on XPro1595 Phase Ib Interim Data of Neuroinflammation in Patients with Alzheimer's Disease
Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab
Targeting soluble TNF to attenuate neuroinflammation in Alzheimer’s disease
The neurogenesis hypothesis: NA-831 for the treatment of Alzheimer’s disease
Phase IIb ELAD trial of liraglutide in mild-moderate Alzheimer’s disease
Inside INmune Bio Volume 6 - EMACC and CDR-SB
Alzheimer's drug Leqembi receives full FDA approval
XPro1595 and Treatment Resistant Depression (TRD) KOL Event
